Jun 9, 2020Paper

IgA MAb blocks SARS-CoV-2 Spike-ACE2 interaction providing mucosal immunity

BioRxiv : the Preprint Server for Biology
Monir EjemelYang Wang


COVID-19 caused by SARS-CoV-2 has become a global pandemic requiring the development of interventions for the prevention or treatment to curtail mortality and morbidity. No vaccine to boost mucosal immunity or as a therapeutic has yet been developed to SARS-CoV-2. In this study we discover and characterize a cross-reactive human IgA monoclonal antibody, MAb362. MAb362 binds to both SARS-CoV and SARS-CoV-2 spike proteins and competitively blocks hACE2 receptor binding, by completely overlapping the hACE2 structural binding epitope. Furthermore, MAb362 IgA neutralizes both pseudotyped SARS-CoV and SARS-CoV-2 in human epithelial cells expressing hACE2. SARS-CoV-2 specific IgA antibodies, such as MAb362, may provide effective immunity against SARS-CoV-2 by inducing mucosal immunity within the respiratory system, a potentially critical feature of an effective vaccine.


Jun 28, 2020·Journal of Virology·John P Moore, P J Klasse
Jan 15, 2021·Immunological Medicine·Norma Saad, Salim Moussa

Related Concepts

Related Feeds

BioRxiv & MedRxiv Preprints

BioRxiv and MedRxiv are the preprint servers for biology and health sciences respectively, operated by Cold Spring Harbor Laboratory. Here are the latest preprint articles (which are not peer-reviewed) from BioRxiv and MedRxiv.

Related Papers

BioRxiv : the Preprint Server for Biology
Monir EjemelYang Wang
BioRxiv : the Preprint Server for Biology
Linlin BaoChuan Qin
Chembiochem : a European Journal of Chemical Biology
Jones de AndradePaulo Augusto Netz
Proceedings of the National Academy of Sciences of the United States of America
Jian ShangFang Li
© 2021 Meta ULC. All rights reserved